Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Sponsor study identifier
observational
113
1 country
10
Study Start
December 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2005
Actual (reported)Study Completion
September 2005
Actual (reported)This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study, "REACH." Blood samples will be collected, a medical and medication history and physical examination will be performed every 6 months for a total of 2 years.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2005
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2002
Date type not reportedThis date has not been verified as actual or estimated.
April 4, 2005
Actual (reported)April 5, 2005
Actual (reported)September 2005
Actual (reported)September 2005
Actual (reported)Demonstrate that few CTL escape mutations occur in HIV-1 specific CD8+ T cell epitopes that are HLA-B*27 and B*57 restricted, when compared to those restricted by HLA-B*35 and B*53.
Demonstrate that few CTL escape mutations occur in HIV-1 specific CD8+ T cell epitopes that are HLA-B\*27 and B\*57 restricted, when compared to those restricted by HLA-B\*35 and B\*53.
96 Weeks
Demonstrate that CD8+ T cells have a high functional avidity to HLA-B*27 and B*57 bound epitopes when compared to those responding to HLA-B*35 and B*53 bound epitopes.
96 Weeks
Subjects who were identified as HLA Class I HLA-B\*27, B\*35, B\*53, and/or B\*57 positive from the REACH study will be contacted for their interest in participating in this study. Only former REACH sites in the ATN will be eligible to enroll subjects into this study.
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
Children's Diagnostic and Treatment Center
Fort Lauderdale, Florida, 33101, United States
University of Miami-Jackson Memorial Medical Center
Miami, Florida, 33101, United States
Cook County Children's Hospital
Chicago, Illinois, 60612, United States
Tulane Medical Center
New Orleans, Louisiana, 70112, United States
University of Maryland
Biomedical HIV-1 related data and samples are available for the time the subjects were enrolled in REACH. HIV-1 genotyping will certainly be possible from these retrospective samples and the stored PBMCs will be evaluated for usefulness in the HIV-1 specific assays. Prospectively, samples will be collected every six months over a two-year period to evaluate both HIV-1 specific CD8+ T cell responses and the dominant HIV-1 genotype longitudinally.
Paul Goepfert, MD
University of Alabama at Birmingham
113 participants (actual enrollment reported by the registry).
First Submitted
April 4, 2005
First Posted
April 5, 2005
Study Start
December 2002
Date type not reportedThis date has not been verified as actual or estimated.
4-Day-A-Week Treatment Plan for HIV Infected Adolescents
Contact the study team to confirm eligibility.
Baltimore, Maryland, 21201, United States
Mount Sinai Medical Center
New York, New York, 10128, United States
Children's Hospital at Montefiore Medical Center
The Bronx, New York, 10467, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Primary Completion
September 2005
Actual (reported)Study Completion
September 2005
Actual (reported)Last Updated
February 28, 2017
Record last verified: 2016-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: